Table 5.

Multivariable Cox Regression Analysis for Cardiovascular Death, Using Weight Loss as Continuous Variable

	Total			Nonobese			Obese
	N=987a			N=716			N=271
	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
Weight lossb	1.30	(1.04–1.61)	0.02	1.28	(0.98–1.06)	0.07	1.41	(0.96–2.07)	0.08
Age	1.04	(1.02–1.06)	<0.001	1.04	(1.02–1.07)	0.001	1.05	(1.01–1.09)	0.02
Female sex	0.62	(0.39–0.98)	0.04	0.62	(0.35–1.11)	0.11	0.44	(0.18–1.06)	0.07
Ischemic etiology	2.07	(1.35–3.19)	0.001	1.81	(1.06–3.08)	0.03	3.36	(1.51–7.48)	0.003
HF duration	1.00	(1.00–1.01)	<0.001	1.00	(1.00–1.01)	<0.001	1.00	(1.00–1.01)	0.49
LVEF	1.00	(0.98–1.01)	0.54	1.00	(0.98–1.01)	0.71	0.99	(0.96–1.02)	0.49
NYHA functional class	1.70	(1.23–2.35)	0.001	1.90	(1.31–2.76)	0.001	1.07	(0.55–2.11)	0.84
Diabetes	1.62	(1.12–2.35)	0.01	1.48	(0.94–2.33)	0.09	2.17	(1.10–4.27)	0.03
BMI	1.02	(0.98–1.06)	0.34	0.96	(0.89–1.04)	0.33	1.08	(0.99–1.19)	0.08
β‐Blockers	0.38	(0.23–0.62)	<0.001	0.42	(0.23–0.75)	0.004	0.34	(0.13–0.86)	0.02
ACEI or ARB	0.44	(0.28–0.71)	0.001	0.39	(0.23–0.67)	0.001	0.84	(0.25–2.84)	0.78
MRA	0.89	(0.61–1.29)	0.54	0.94	(0.60–1.46)	0.78	0.85	(0.42–1.72)	0.64

ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.

^aThirteen patients excluded because of unknown cause of death.

^bPer 1 SD decrease in weight.